APOE genotype as a risk factor for ischemic cerebrovascular disease

A meta-analysis

Mark O. McCarron, David Delong, Mark J. Alberts

Research output: Contribution to journalArticle

220 Citations (Scopus)

Abstract

Objective: To determine whether a specific apolipoprotein E (APOE) polymorphism is a risk factor for ischemic cerebrovascular disease (CVD; stroke or TIA). Background: The APOE ε4 allele is overrepresented in AD, atherosclerosis, and ischemic heart disease. In addition, ε4 carriers have higher plasma cholesterol levels than non-ε4 carriers. Methods: Using Medline (OVID and PubMed), a search was performed for all studies that examined APOE in ischemic CVD. The authors identified nine case-control studies that were suitable for analysis. Results: There were 926 patients with ischemic stroke or TIAs and 890 age- and sex-matched control subjects. Overall analysis revealed a significantly higher APOE-ε4 allelic frequency in affected patients compared with control subjects (0.14 versus 0.09; odds ratio, 1.68; 95% CI, 1.36 to 2.09; p < 0.001). There was a significant excess of the ε3 allele (0.85 versus 0.80) but not the ε2 allele (0.06 versus 0.06) in the control subjects compared with the ischemic CVD patients. Seven studies had data on APOE genotypes. Carriers of ε4 were more frequent among ischemic CVD patients than control subjects (27% versus 18%; odds ratio, 1.73; 95% CI, 1.34 to 2.23; p < 0.001). Conclusions: The APOE-ε4 allele and carriers of ε4 are more frequent among patients with ischemic CVD compared with control subjects. The ε2 allele does not appear to be protective for ischemic CVD. These findings imply a role for the APOE genotype in the pathogenesis of some cases of ischemic CVD.

Original languageEnglish (US)
Pages (from-to)1308-1311
Number of pages4
JournalNeurology
Volume53
Issue number6
StatePublished - Oct 12 1999

Fingerprint

Cerebrovascular Disorders
Apolipoproteins E
Meta-Analysis
Apolipoprotein E4
Alleles
Genotype
Stroke
Odds Ratio
Hypercholesterolemia
PubMed
Myocardial Ischemia
Case-Control Studies
Atherosclerosis

Keywords

  • Apolipoprotein E
  • Ischemic cerebrovascular disease

ASJC Scopus subject areas

  • Neuroscience(all)

Cite this

APOE genotype as a risk factor for ischemic cerebrovascular disease : A meta-analysis. / McCarron, Mark O.; Delong, David; Alberts, Mark J.

In: Neurology, Vol. 53, No. 6, 12.10.1999, p. 1308-1311.

Research output: Contribution to journalArticle

McCarron, Mark O. ; Delong, David ; Alberts, Mark J. / APOE genotype as a risk factor for ischemic cerebrovascular disease : A meta-analysis. In: Neurology. 1999 ; Vol. 53, No. 6. pp. 1308-1311.
@article{683ddaa272e54bcd9a69b630f5b73a45,
title = "APOE genotype as a risk factor for ischemic cerebrovascular disease: A meta-analysis",
abstract = "Objective: To determine whether a specific apolipoprotein E (APOE) polymorphism is a risk factor for ischemic cerebrovascular disease (CVD; stroke or TIA). Background: The APOE ε4 allele is overrepresented in AD, atherosclerosis, and ischemic heart disease. In addition, ε4 carriers have higher plasma cholesterol levels than non-ε4 carriers. Methods: Using Medline (OVID and PubMed), a search was performed for all studies that examined APOE in ischemic CVD. The authors identified nine case-control studies that were suitable for analysis. Results: There were 926 patients with ischemic stroke or TIAs and 890 age- and sex-matched control subjects. Overall analysis revealed a significantly higher APOE-ε4 allelic frequency in affected patients compared with control subjects (0.14 versus 0.09; odds ratio, 1.68; 95{\%} CI, 1.36 to 2.09; p < 0.001). There was a significant excess of the ε3 allele (0.85 versus 0.80) but not the ε2 allele (0.06 versus 0.06) in the control subjects compared with the ischemic CVD patients. Seven studies had data on APOE genotypes. Carriers of ε4 were more frequent among ischemic CVD patients than control subjects (27{\%} versus 18{\%}; odds ratio, 1.73; 95{\%} CI, 1.34 to 2.23; p < 0.001). Conclusions: The APOE-ε4 allele and carriers of ε4 are more frequent among patients with ischemic CVD compared with control subjects. The ε2 allele does not appear to be protective for ischemic CVD. These findings imply a role for the APOE genotype in the pathogenesis of some cases of ischemic CVD.",
keywords = "Apolipoprotein E, Ischemic cerebrovascular disease",
author = "McCarron, {Mark O.} and David Delong and Alberts, {Mark J.}",
year = "1999",
month = "10",
day = "12",
language = "English (US)",
volume = "53",
pages = "1308--1311",
journal = "Neurology",
issn = "0028-3878",
publisher = "Lippincott Williams and Wilkins",
number = "6",

}

TY - JOUR

T1 - APOE genotype as a risk factor for ischemic cerebrovascular disease

T2 - A meta-analysis

AU - McCarron, Mark O.

AU - Delong, David

AU - Alberts, Mark J.

PY - 1999/10/12

Y1 - 1999/10/12

N2 - Objective: To determine whether a specific apolipoprotein E (APOE) polymorphism is a risk factor for ischemic cerebrovascular disease (CVD; stroke or TIA). Background: The APOE ε4 allele is overrepresented in AD, atherosclerosis, and ischemic heart disease. In addition, ε4 carriers have higher plasma cholesterol levels than non-ε4 carriers. Methods: Using Medline (OVID and PubMed), a search was performed for all studies that examined APOE in ischemic CVD. The authors identified nine case-control studies that were suitable for analysis. Results: There were 926 patients with ischemic stroke or TIAs and 890 age- and sex-matched control subjects. Overall analysis revealed a significantly higher APOE-ε4 allelic frequency in affected patients compared with control subjects (0.14 versus 0.09; odds ratio, 1.68; 95% CI, 1.36 to 2.09; p < 0.001). There was a significant excess of the ε3 allele (0.85 versus 0.80) but not the ε2 allele (0.06 versus 0.06) in the control subjects compared with the ischemic CVD patients. Seven studies had data on APOE genotypes. Carriers of ε4 were more frequent among ischemic CVD patients than control subjects (27% versus 18%; odds ratio, 1.73; 95% CI, 1.34 to 2.23; p < 0.001). Conclusions: The APOE-ε4 allele and carriers of ε4 are more frequent among patients with ischemic CVD compared with control subjects. The ε2 allele does not appear to be protective for ischemic CVD. These findings imply a role for the APOE genotype in the pathogenesis of some cases of ischemic CVD.

AB - Objective: To determine whether a specific apolipoprotein E (APOE) polymorphism is a risk factor for ischemic cerebrovascular disease (CVD; stroke or TIA). Background: The APOE ε4 allele is overrepresented in AD, atherosclerosis, and ischemic heart disease. In addition, ε4 carriers have higher plasma cholesterol levels than non-ε4 carriers. Methods: Using Medline (OVID and PubMed), a search was performed for all studies that examined APOE in ischemic CVD. The authors identified nine case-control studies that were suitable for analysis. Results: There were 926 patients with ischemic stroke or TIAs and 890 age- and sex-matched control subjects. Overall analysis revealed a significantly higher APOE-ε4 allelic frequency in affected patients compared with control subjects (0.14 versus 0.09; odds ratio, 1.68; 95% CI, 1.36 to 2.09; p < 0.001). There was a significant excess of the ε3 allele (0.85 versus 0.80) but not the ε2 allele (0.06 versus 0.06) in the control subjects compared with the ischemic CVD patients. Seven studies had data on APOE genotypes. Carriers of ε4 were more frequent among ischemic CVD patients than control subjects (27% versus 18%; odds ratio, 1.73; 95% CI, 1.34 to 2.23; p < 0.001). Conclusions: The APOE-ε4 allele and carriers of ε4 are more frequent among patients with ischemic CVD compared with control subjects. The ε2 allele does not appear to be protective for ischemic CVD. These findings imply a role for the APOE genotype in the pathogenesis of some cases of ischemic CVD.

KW - Apolipoprotein E

KW - Ischemic cerebrovascular disease

UR - http://www.scopus.com/inward/record.url?scp=0032874367&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0032874367&partnerID=8YFLogxK

M3 - Article

VL - 53

SP - 1308

EP - 1311

JO - Neurology

JF - Neurology

SN - 0028-3878

IS - 6

ER -